Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer

(2016) Chau Dang et al.   JAMA Oncology

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study

(2015) Hart A. Goldhar et al.   JNCI-Journal of the National Cancer Institute

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

(2015) Sara M. Tolaney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

The anthracycline–trastuzumab interaction: a lesson in not jumping to confusion

(2015) Michael S. Ewer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study

(2015) Hart A. Goldhar et al.   JNCI-Journal of the National Cancer Institute

Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival

(2014) Shi-Yi Wang et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer treatment and survivorship statistics, 2014

(2014) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management

(2014) Judy Truong et al.   CANADIAN JOURNAL OF CARDIOLOGY

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

(2014) Evandro de Azambuja et al.   JOURNAL OF CLINICAL ONCOLOGY

2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary

(2013) Clyde W. Yancy et al.   CIRCULATION

Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer

(2013) Mariana Chavez-MacGregor et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Biomarkers, Cardiotoxicity, and Active Collaboration

(2013) Daniel J. Lenihan   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study

(2013) Stephen E Jones et al.   LANCET ONCOLOGY

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis

(2012) L. Tarantini et al.   ANNALS OF ONCOLOGY

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2012) Jersey Chen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

(2012) E. J. A. Bowles et al.   JNCI-Journal of the National Cancer Institute

Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer

(2011) Luigi Tarantini et al.   JOURNAL OF CARDIAC FAILURE

Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics

(2011) Edoardo Colzani et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

(2010) Marion Procter et al.   JOURNAL OF CLINICAL ONCOLOGY

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

(2010) Stuart D. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

(2010) Daniela Cardinale et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

(2009) Michele Y. Halyard et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Complications of Cancer Therapy

(2009) Edward T.H. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

(2008) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY